ArticleBMC endocrine disorders2025
A retrospective analysis of real-world height outcomes of growth hormone treatment in Syrian children.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth hormone (GH) therapy is an effective option for short-stature children. In this study, we aimed to report our real-life experience of using GH treatment in Syria by comparing its effects in four different indications: growth hormone deficiency (GHD), idiopathic short stature (ISS), small for gestational age (SGA), and Turner syndrome (TS).
methodsWe evaluated retrospectively the anthropometric data of 200 short-stature children who started therapy between 4 and 9 years and were treated between Jan-2018 and Jun-2023. Auxological parameters included growth velocity (GV), height (Ht), and bone age (BA).
resultsAfter four years of GH therapy, all groups showed a significant increase in GVSDS and HtSDS (p < 0.00 for both). GHD revealed the most improvement (mean ΔGVSDS: 3.43) versus those with other indications (ISS: 2.39, SGA: 2.54, TS: 1.77). The mean ΔHtSDS observed ranged from a minimum of 0.82 in children with TS, 1.21 in SGA, and 1.48 in ISS to a maximum of 2.06 in GHD. The mean bone age-chronological age was − 1.59 at baseline and − 1.67 after 4 years (p = 0.18). The highest percentage of improvement in GVSDS and HtSDS was during the first year of treatment (for all groups, p < 0.00).
conclusionsFor Syrian children with GHD, ISS, SGA, and TS, GH therapy provides an efficient treatment choice. GH therapy was most effective in those with GHD and during the first year of treatment. These results support the use of GH therapy for Syrian short-stature children. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.